Citations (49)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Pan Ran, Juan Li, Xingye Wu, Hao Yang & Jun Zhang. (2022) Primary Localized Gastrointestinal Stromal Tumors: Medication Adherence and Prognosis According to Gender. Patient Preference and Adherence 16, pages 2077-2087.
Read now
Read now
Bee Kim Tan, Ping Chong Bee, Siew Siang Chua & Li-Chia Chen. (2021) Monitoring and Improving Adherence to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia: A Systematic Review. Patient Preference and Adherence 15, pages 2563-2575.
Read now
Read now
Fiorenzo Santoleri, Elena Ranucci, Gaetano La Barba, Irene Colasanto, Matilde Scaldaferri, Francesco Cattel, Francesca Federici, Chiara Rossi, Katiuscia Di Biagio, Anna Rita Scortechini, Felice Musicco, Giancarlo Torquati, Angela Frazzetto, Antonietta Vozza, Caterina de Rosa, Rosaria Lanzillo, Maria Monteverde, Luigia Luciano, Fabrizio Pane, Arianna Pasquazi, Maria Grazia Celeste, Maria Cantonetti, Luca Franceschini, Manuela Rizzo & Alberto Costantini. (2021) Adherence, persistence and efficacy of dasatinib and nilotinib in the treatment of patients resistant or intolerant to imatinib with chronic myeloid leukemia in chronic phase: an Italian multicenter study over two years in real life. Current Medical Research and Opinion 37:3, pages 477-481.
Read now
Read now
B. Douglas Smith, Jun Liu, Dominick Latremouille-Viau, Annie Guerin, Daniel Fernandez & Lei Chen. (2016) Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Current Medical Research and Opinion 32:5, pages 817-827.
Read now
Read now
Lisa J. McGarry, Yaozhu J. Chen, Victoria Divino, Shibani Pokras, Catherine R. Taylor, Julie Munakata, Christopher C. Nieset, Hui Huang, Elias Jabbour & Daniel C. Malone. (2016) Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Current Medical Research and Opinion 32:2, pages 289-299.
Read now
Read now
Runzhe Chen & Baoan Chen. (2015) The role of dasatinib in the management of chronic myeloid leukemia. Drug Design, Development and Therapy 9, pages 773-779.
Read now
Read now
Susanne Liewer & Ashley N Huddleston. (2015) Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients. Expert Review of Anticancer Therapy 15:4, pages 453-464.
Read now
Read now
Melea A. Ward, Gang Fang, Kristy L. Richards, Christine M. Walko, Stephanie R. Earnshaw, Laura E. Happe & Susan J. Blalock. (2015) Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Current Medical Research and Opinion 31:2, pages 289-297.
Read now
Read now
Meri Kekäle, Kimmo Talvensaari, Perttu Koskenvesa, Kimmo Porkka & Marja Airaksinen. (2014) Chronic myeloid leukemia patients’ adherence to peroral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Preference and Adherence 8, pages 1619-1627.
Read now
Read now
Stephen Harnicar & Sherry Mathew. (2014) Spotlight on nilotinib in the treatment of chronic myelogenous leukemia. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 61-67.
Read now
Read now
Fausto R. Loberiza$suffix/text()$suffix/text(), Andrew C. Cannon, Anthony J. Cannon & Philip J. Bierman. (2014) Insights on practice variations in the management of lymphoma and leukemia. Leukemia & Lymphoma 55:11, pages 2449-2456.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase. Current Medical Research and Opinion 30:7, pages 1345-1352.
Read now
Read now
Annie Guérin, Lei Chen, Katherine Dea, Eric Q. Wu & Stuart L. Goldberg. (2014) Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. Journal of Medical Economics 17:2, pages 89-98.
Read now
Read now
Lonneke Timmers, Christel C. L. M. Boons, Femke Kropff, Peter M. van de Ven, Eleonora L. Swart, Egbert F. Smit, Sonja Zweegman, Judith R. Kroep, Johanna N. H. Timmer-Bonte, Epie Boven & Jacqueline G. Hugtenburg. (2014) Adherence and patients’ experiences with the use of oral anticancer agents. Acta Oncologica 53:2, pages 259-267.
Read now
Read now
Chan Shen, Chun-Ru Chien, Daniel M Geynisman, Fabrice Smieliauskas & Ya-Chen T Shih. (2014) A review of economic impact of targeted oral anticancer medications. Expert Review of Pharmacoeconomics & Outcomes Research 14:1, pages 45-69.
Read now
Read now
James D. Griffin, Annie Guerin, Lei Chen, Alexander R. Macalalad, Jiayuan Luo, Raluca Ionescu-Ittu & Eric Qiong Wu. (2013) Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib – a retrospective chart review analysis. Current Medical Research and Opinion 29:6, pages 623-631.
Read now
Read now
Lonneke Timmers, Eleonora L Swart, Christel CLM Boons, Dirk Mangnus, Peter M van de Ven, Godefridus J Peters, Epie Boven & Jacqueline G Hugtenburg. (2012) The use of capecitabine in daily practice: a study on adherence and patients’ experiences. Patient Preference and Adherence 6, pages 741-748.
Read now
Read now
Annie Guérin, Lei Chen, Eric Q. Wu, Diego Ponce de Leon & James D. Griffin. (2012) A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting. Current Medical Research and Opinion 28:7, pages 1155-1162.
Read now
Read now
Marianne Ulcickas Yood, Susan A. Oliveria, Mark Cziraky, Ishan Hirji, Muhammad Hamdan & Catherine Davis. (2012) Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Current Medical Research and Opinion 28:2, pages 213-219.
Read now
Read now
Articles from other publishers (30)
Rory M. Shallis, Rong Wang, Amer M. Zeidan, Scott F. Huntington, Natalia Neparidze, Jessica M. Stempel, Lourdes M. Mendez, Mengyang Di, Xiaomei Ma & Nikolai A. Podoltsev. (2023) Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 7:13, pages 3213-3224.
Crossref
Crossref
Samantha E Clark, Zachary A Marcum, Jerald P Radich & Aasthaa Bansal. (2020) Predictors of tyrosine kinase inhibitor adherence trajectories in patients with newly diagnosed chronic myeloid leukemia. Journal of Oncology Pharmacy Practice 27:8, pages 1842-1852.
Crossref
Crossref
Yundeok Kim, Tae-Hwa Go, Jaeyeon Jang, Jii Bum Lee, Seung Taek Lim, Kwang Yong Shim, Jong In Lee & Jee Hyun Kong. (2021) Survival impact of adherence to tyrosine kinase inhibitor in chronic myeloid leukemia. The Korean Journal of Internal Medicine 36:6, pages 1450-1458.
Crossref
Crossref
Michael W. DeiningerNeil P. ShahJessica K. AltmanEllin BermanRavi BhatiaBhavana BhatnagarDaniel J. DeAngeloJason GotlibGabriela HobbsLori ManessMonica MeadLeland MethenySanjay MohanJoseph O. MooreKiran NaqviVivian OehlerArnel M. PalleraMrinal PatnaikKeith PratzIskra PusicMichal G. RoseB. Douglas SmithDavid S. SnyderKendra L. SweetMoshe TalpazJames ThompsonDavid T. Yang, Kristina M. Gregory & Hema Sundar. (2020) Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:10, pages 1385-1415.
Crossref
Crossref
Christel C. L. M. Boons, Lonneke Timmers, Jeroen J. W. M. Janssen, Peter E. Westerweel, Nicole M. A. Blijlevens, Willem M. Smit, Imke H. Bartelink, Janneke A. Wilschut, Eleonora L. Swart, N. Harry Hendrikse & Jacqueline G. Hugtenburg. (2020) Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. European Journal of Clinical Pharmacology 76:9, pages 1213-1226.
Crossref
Crossref
Hsiao Ling Phuar, Charles E. Begley, Wenyaw Chan & Trudy Millard Krause. (2020) Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia. American Journal of Clinical Oncology 43:7, pages 517-525.
Crossref
Crossref
Jee Hyun Kong, Elliott F. Winton, Leonard T. Heffner, Manila Gaddh, Brittany Hill, Jessica Neely, Angela Hatcher, Meena Joseph, Martha Arellano, Fuad El-Rassi, Audrey Kim, Jean Hanna Khoury & Vamsi K. Kota. (2020) Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors. Journal of Clinical Medicine 9:5, pages 1542.
Crossref
Crossref
Hsiao Ling PhuarCharles E. BegleyWenyaw ChanTrudy Millard Krause. (2019) Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study. Journal of Managed Care & Specialty Pharmacy 25:10, pages 1140-1150.
Crossref
Crossref
Jie Fu, Yuchen Liu, Houwen Lin & Bin Wu. (2018) Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review. Clinical Drug Investigation 38:12, pages 1167-1178.
Crossref
Crossref
Mariana M. Fachi, Fernanda S. Tonin, Leticia P. Leonart, Karina S. Aguiar, Luana Lenzi, Bonald C. Figueiredo, Fernando Fernandez-Llimos & Roberto Pontarolo. (2018) Comparative efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukaemia: A systematic review and network meta-analysis. European Journal of Cancer 104, pages 9-20.
Crossref
Crossref
Avi Leader, Anat Gafter-Gvili, Noam Benyamini, Juliet Dreyer, Bronya Calvarysky, Alina Amitai, Osnat Yarchovsky-Dolberg, Giora Sharf, Eric Tousset, Opher Caspi, Martin Ellis, Itai Levi, Pia Raanani & Sabina De Geest. (2018) Identifying Tyrosine Kinase Inhibitor Nonadherence in Chronic Myeloid Leukemia: Subanalysis of TAKE-IT Pilot Study. Clinical Lymphoma Myeloma and Leukemia 18:9, pages e351-e362.
Crossref
Crossref
Nazia Rashid, Han A Koh, Kathy J Lin, Brian Stwalley & Eugene Felber. (2017) Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. Journal of Oncology Pharmacy Practice 24:4, pages 253-263.
Crossref
Crossref
Michael Stokes, Carolina Reyes, Yu Xia, Veronica Alas, Hans-Peter Goertz & Luke Boulanger. (2017) Impact of pharmacy channel on adherence to oral oncolytics. BMC Health Services Research 17:1.
Crossref
Crossref
Linda Bouwman, Corien M. Eeltink, Otto Visser, Jeroen J. W. M. Janssen & Jolanda M. Maaskant. (2017) Prevalence and associated factors of medication non-adherence in hematological-oncological patients in their home situation. BMC Cancer 17:1.
Crossref
Crossref
Michio Kimura. (2016) Investigation into the Establishment of Indicators for Pharmaceutical Intervention in Cancer Pharmacotherapyがん薬物療法における薬学的介入の指標構築に関する研究. YAKUGAKU ZASSHI 136:10, pages 1379-1384.
Crossref
Crossref
Joseph A. Greer, Nicole Amoyal, Lauren Nisotel, Joel N. Fishbein, James MacDonald, Jamie Stagl, Inga Lennes, Jennifer S. Temel, Steven A. Safren & William F. Pirl. (2016) A Systematic Review of Adherence to Oral Antineoplastic Therapies. The Oncologist 21:3, pages 354-376.
Crossref
Crossref
Alix E. Hall, Chris Paul, Jamie Bryant, Marita C. Lynagh, Philip Rowlings, Anoop Enjeti & Hannah Small. (2016) To adhere or not to adhere: Rates and reasons of medication adherence in hematological cancer patients. Critical Reviews in Oncology/Hematology 97, pages 247-262.
Crossref
Crossref
Marie Barillet, Virginie Prevost, Florence Joly & Bénédicte Clarisse. (2015) Oral antineoplastic agents: how do we care about adherence?. British Journal of Clinical Pharmacology 80:6, pages 1289-1302.
Crossref
Crossref
Kevin B. Knopf, Victoria Divino, Lisa McGarry, Yaozhu J. Chen, Shibani Pokras, Julie Munakata, Catherine Taylor, Daniel Ng, Christopher Nieset & Hui Huang. (2015) Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia. Clinical Lymphoma Myeloma and Leukemia 15:11, pages e163-e171.
Crossref
Crossref
MICHIO KIMURA, KEIJI NAKASHIMA, EISEKI USAMI, MINA IWAI, TOSHIYA NAKAO, TOMOAKI YOSHIMURA, HIROMI MORI & HITOMI TERAMACHI. (2015) Adherence and awareness of the therapeutic intent of oral anticancer agents in an outpatient setting. Oncology Letters 9:5, pages 2341-2346.
Crossref
Crossref
MICHIO KIMURA, EISEKI USAMI, MINA IWAI, TOSHIYA NAKAO, TOMOAKI YOSHIMURA, HIROMI MORI, TADASHI SUGIYAMA & HITOMI TERAMACHI. (2014) Oral anticancer agent medication adherence by outpatients. Oncology Letters 8:5, pages 2318-2324.
Crossref
Crossref
Emmanuel Giménez García, M. Angeles Portero, Concepción Boqué, Asunción Echeveste, Raquel de Paz, Santiago del Castillo, Reyes Calzada, Juan Diego González & Valentín García-Gutiérrez. (2014) Análisis del impacto presupuestario tras la comercialización de nilotinib en el tratamiento de primera línea en pacientes con leucemia mieloide crónica de nuevo diagnóstico en España. PharmacoEconomics Spanish Research Articles 11:1, pages 5-14.
Crossref
Crossref
David Cella, Cindy J. Nowinski & Olga Frankfurt. (2014) The Impact of Symptom Burden on Patient Quality of Life in Chronic Myeloid Leukemia. Oncology 87:3, pages 133-147.
Crossref
Crossref
M. Verbrugghe, S. Verhaeghe, K. Lauwaert, D. Beeckman & A. Van Hecke. (2013) Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: A systematic review. Cancer Treatment Reviews 39:6, pages 610-621.
Crossref
Crossref
Adam Gater, Louise Heron, Linda Abetz-Webb, John Coombs, Jeff Simmons, François Guilhot & Delphine Rea. (2012) Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia. Leukemia Research 36:7, pages 817-825.
Crossref
Crossref
Elias J. Jabbour, Hagop Kantarjian, Lina Eliasson, A. Megan Cornelison & David Marin. (2012) Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia. American Journal of Hematology 87:7, pages 687-691.
Crossref
Crossref
Peter C. Trask, Debanjali Mitra, Shrividya Iyer, Sean D. Candrilli & James A. Kaye. (2012) Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. International Journal of Hematology 95:5, pages 535-544.
Crossref
Crossref
Lina Eliasson. (2012) Treatment adherence in chronic myeloid leukemia: a systematic review of the literature. Clinical Practice 9:1, pages 87-100.
Crossref
Crossref
Lonneke Timmers, Christel CLM Boons, Dirk Mangnus, Josee E Moes, Eleonora L Swart, Epie Boven, Egbert F Smit & Jacqueline G Hugtenburg. (2011) The use of erlotinib in daily practice: a study on adherence and patients' experiences. BMC Cancer 11:1.
Crossref
Crossref
Marie P. ShiehMasato MitsuhashiMichael Lilly. (2011) Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML. Clinical Medicine Insights: Oncology 5, pages CMO.S6416.
Crossref
Crossref